Generic Name: ataluren
Brand Name: Translarna
Manufacturer: PTC Therapeutics Canada ULC
Indications: Dystrophinopathy
Manufacturer Requested Reimbursement Criteria1:
For the treatment of dystrophinopathy resulting from a nonsense mutation in the dystrophin gene.
Submission Type: Initial
Project Status: Cancelled
Biosimilar: No
Fee Schedule: Pending
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.